Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after the stock rebounded ...

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...

This will be the first time the option has been taken up since it was introduced at the beginning of 2025, under the Medical ...

Jax Media alums Tony Hernandez and Lilly Burns have launched Counterpart Studios, with former MRC Television chief Elise ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

The two main players in the global obesity market are Eli Lilly LLY and Novo Nordisk NVO, with their respective GLP-1 injectable therapies, Zepbound and Wegovy, leading the field. Although Zepbound ...

Despite current headwinds like tariffs and patent expirations, I see long-term opportunity in top-tier pharmaceutical stocks ...

Eli Lilly and Company (NYSE: LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded ...

Eli Lilly and Company (NYSE: LLY) is one of the Good Stocks to Invest in Now. On August 7, Eli Lilly and Company (NYSE:LLY) ...

An updated guideline on pharmacotherapy of obesity management in adults includes six new and seven revised recommendations, ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

This week, drugmakers had a scare when President Trump threatened to levy tariffs of up to 250% on imported pharmaceuticals.